Arca
Skip to content
Tools
Tools

Unit Dose Valsartan Tablets

Recall D-0967-2018, part of FDA recall event 80557. See Major Pharmaceuticals's company page.

MAJOR PHARMACEUTICALS started this Class II drug recall on Jul 18, 2018 (n/a); FDA lists it as terminated, terminated Oct 2, 2022.

  • Classification: Class II
  • Started: Jul 18, 2018
  • Status: Terminated
  • Products in this event: 2

Why It Was Recalled

Class II

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Record

Product
Unit Dose Valsartan Tablets, USP. 160 mg. Rx only.,Distributed by: Major Pharmaceuticals, Livonia, MI 48152, NDC# 0904-6594-61. NDC# 0904-6595-61.
Quantity
4,556 cartons
Lots and codes
Major Label Unit Dose 10 x 10 Cartons 160 mg Item # 302087. Lot# T-01269 (Expiry: 7/18). Lot# T-01524 (Expiry: 2/19). Lot# T-01646 (Expiry: 5/19). Lot# T-01668 (Expiry: 5/19). Lot# T-01788 (Expiry: 5/19).
Distribution
Nationwide.
Recalling firm
MAJOR PHARMACEUTICALS, Livonia, MI, United States
How the firm notified
N/A
FDA classified
Jul 20, 2018

Other Products in This Recall

Recall event 80557

MAJOR PHARMACEUTICALS's Other Recalls

Newest first, one product per recall event; search them all

FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.